Welche Effektgröße kann von RDN erwartet werden und welche Auswirkungen könnte dies auf die kardiovaskuläre Morbidität und Mortalität haben?
Hypertension and Renal Denervation. This resource helps non-invasive cardiologists, hypertension specialists, general practitioners, and nephrologists understand the benefits of Renal Denervation...
Hypertension and Renal Denervation. This resource helps non-invasive cardiologists, hypertension specialists, general practitioners, and nephrologists understand the benefits of Renal Denervation as an adjunctive therapy for treating Hypertension.
It answers frequently asked questions with the latest expert opinions, guideline summaries, and essential information for practical adoption in managing uncontrolled and resistant Hypertension.
Learn about patient selection, key evidence for safety, effectiveness, durability, and integrating Renal Denervation into your practice.
Supported by an educational grant from Medtronic.
Speakers
Felix Mahfoud
Speaker
Professor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and... Professor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and Cardiology at Saarland University Hospital, and Affiliate/Visiting Professor Harvard-MIT Biomedical Engineering, Institute of Medical Engineering and Science, Cambridge, US. Professor Mahfoud completed training in Cardiology and Interventional Cardiology at the Department for Internal Medicine III, Saarland University Hospital, Germany in 2014. Since 2017, he has served as Vice Chairman of the ‘Working Group on Interventional Hypertension Treatment’ for the European Society of Hypertension, and as a Committee Member of the 2018 Hypertension Guidelines.